UCB (OTCMKTS:UCBJF) Stock Price Passes Above 50-Day Moving Average - Here's Why

Key Points

• UCB SA's share price has surged above its 50-day moving average, last trading at $238.84, indicating potential upward momentum.
• Morgan Stanley has upgraded UCB's stock rating to "overweight", contributing to a consensus rating of "Buy" from analysts.
• The company specializes in biopharmaceuticals, focusing on treatment for neurology and immunology diseases with a strong product portfolio including Cimzia and Vimpat.

Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $216.96 and traded as high as $238.84. UCB shares last traded at $238.84, with a volume of 53 shares changing hands.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded shares of UCB to an "overweight" rating in a report on Monday, June 23rd. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, UCB currently has a consensus rating of "Buy".

UCB Stock Up 0.9%

The firm has a 50-day moving average price of $219.45 and a 200-day moving average price of $191.59. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.